IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting
Results from OVATION 2 Study of IMNN-001 to be highlighted in late-breaking acceptanceCompany also announces FDA End-of-Phase 2 in-person meeting ...
FierceBiotech22d
MeiraGTx's gene therapy improves motor function and quality of life in phase 2 Parkinson's trial
MeiraGTx is looking to march its Parkinson’s disease treatment forward into phase 3 after the gene therapy improved motor ability and quality of life in a small midphase trial. A total of 14 ...
Business Wire1mon
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1 ...
Based on these results, Rina-S 120 mg/m 2 has been selected for further evaluation in a Phase 3 trial for patients with advanced ovarian cancer, which is expected to start in 2024. "Ovarian cancer ...
Sagimet Biosciences completes End-of-Phase 2 meeting with FDA on denifanstat
Sagimet Biosciences (SGMT) announced the completion of end-of-Phase 2 interactions with the U.S. Food and Drug Administration, supporting the ...
ophthalmologytimes8d
EyePoint Pharmaceuticals announces positive interim 16-Week data for ongoing Phase 2 VERONA clinical trial of Duravyu for DME
According to the company, Duravyu 2.7mg demonstrated an early and sustained anatomical improvement mirroring BCVA results with a 68 micron reduction in CST. Full topline data is anticipated in Q1 of ...